Biological Times

Volume No. 3 | Issue No. 8 | Pages 7-8

Engineering Immunity: The Role of Synthetic Peptides in Modern Vaccinology

Duaa Hayat*, Rais Ahmed, Raheeq-ul-Makhtoom, Jaweria Muslim and Sherish Latif

Department of Microbiology, Cholistan University of Veterinary and Animal Sciences, Bahawalpur

*Corresponding Author: duaahayat05@gmail.com

ABSTRACT

The principles of vaccinology have been expanded with some help of synthetic peptides in a very creative manner. This will explain the essence of synthetic peptides in modern vaccinology as it applies synthetic peptides in designing vaccines that are accurate, customizable, and expandable to target various infectious diseases and immune system challenges. When the vaccines need to elicit a specific immune response with low likelihood of an adverse reaction, then small groups of amino acids referred to as synthetic peptides are vital for vaccine production. It will give information on how certain characteristics of vaccines such as immunogenicity and stability together with safety issues depending on the formulation of synthetic peptides in the vaccine formulation are enhanced through the discussion of various types of peptide synthesis. It gives details of synthetic peptide technology is being to combat against infectious diseases globally for the improvement of human health.

Keywords: Vaccine, Peptides, Immune response, Epitope design, Immunogenicity

Introduction

Thus, vaccinology which is the branch of scientific study of vaccines for controlling infectious diseases can be regarded as a field that has significantly developed after the use of the first vaccine in 1796 by Edward Jenner (1). Conventional vaccines have therefore employed use of weakened or inactivated pathogens or subunits of the antigens to elicit immune responses in the recipient. Although these vaccines have shown a great extent in preventing and eradicating innumerable diseases across the globe, their production tends to be challenging, include strict precautions when administering, and are restricted to mobilizing certain immune responses.

New technologies in the field of Biotechnology and immunology have been enabling the development of new generation vaccines that are technically more effective and safer. Of these innovations, synthetic peptides have received much interest in the past few years due to its uniqueness hold for the alteration of the approach of designing vaccines mostly and improving the effectivity (2). Synthetic peptides are short sequences of amino acid residues that can be produced to recreate particular sequences in pathogens, which will elicit immunity but not the disease.

The Fundamentals of Synthetic Peptides

- **Synthetic Peptide Vaccines and Their Mechanisms of Action**

Synthetic peptide vaccines are the strongest weapon in the modern vaccinological treatment. These vaccines operate through several key mechanisms:

I. Epitope Presentation and T cell Activation

Actually, synthetic peptide vaccines contain precisely certain peptide sequences which relate to epitopes of pathogens or tumors (3). These peptides are displayed to the immune system by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs) as shown in figure 1. This presentation is essential in the activation of T cells especially ,CD4+ helper T cells as well as the CD8+ cytotoxic T cells (4). When these peptides are recognized, T cells get activated, and start to divide as well as mount a very effective immune campaign against the target antigen.

II. Antibody Production

Although synthetic peptide mainly elicits cell mediated response, they do also bring about humoral response. If peptides are tested on B cells, then they are capable of stimulating production of antibodies related to the peptide or the antigen it corresponds to (5). These antibodies are capable of the direct neutralization of pathogens or the recruitment of pathogens to areas where they will be destroyed through opsonization and complement activation.

III. Immunogenicity Enhancement

To improve the immunogenicity of the synthetic peptide vaccines they may be combined with adjuvants. These are substances that enhance the immunity of the body to the existing vaccines. It can do so through enhancing the display of the antigen on the cell surface, activating the innate arm of immunity or by increasing the time that the given peptide spends within the immune system (6). This results in a stronger and longer lasting capacity of the immune system.

IV. Targeted Immune Response

In comparison with other types of vaccines synthetic peptide vaccines have the following benefits one of the most important of them is ability to stimulate the required immune response. These vaccines work by synthesizing peptides that will a epitopes of a pathogen or tumor cells so that the immune system will home in on such cells (7). Such specificity can help to minimize side effects and damage to the healthy cells thus making the synthetic peptide vaccines suitable for the treatment of cancers.

V. Memory Formation

Realistically good synthetic peptide vaccines can also help in the development of the immune memory. Memory T cells and B cells which have the ability to recognize these synthetic peptides (8). This implies that adaptive immunity has the capability to respond more efficiently at a faster rate with long-standing impact to the pathogen or tumor antigen, when the actual pathogen or tumor antigen is introduced.



Fig. 1: Presentation of antigen by Antigen presenting cell after the delivery of vaccine.

Synthetic Peptide Vaccines: Design and Immunogenic Mechanisms

Synthetic peptide vaccines are made up of small protein sequences that are closely related to the surface loops of the pathogen (9). These epitopes are antigenic, which means that they are recognized by the immune system and this sets of a chain of events that result to the formation of antibodies as well as cell mediated immunity. The process of developing peptide vaccines is centered in the identification of both potent and invariant epitopes on various strains of the pathogen.

There are diverse approaches that can be employed for the strengthening of immunogenicity of peptide vaccines, for instance, coupling of peptides to carrier proteins, usage of adjuvants, and combination of multiple epitopes in a single immunizing construct. If the carrier protein is a toxin, T-cell help can be obtained and enhanced immune response can be observed. To increase immunogenicity of the designed peptide vaccines, additional adjuvants like aluminum salts or oil-in-water emulsions which engage innate signaling pathways (10).

Applications of Synthetic Peptide Vaccines in Vaccinology

To cite this article: Hayat D, R Ahmad, RU Makhtoom, J Muslim & S Latif. Engineering Immunity: The Role of Synthetic Peptides in Modern Vaccinology. Biological Times. 2024 August 3(8): 7-8

Peptide vaccines are multitalented to neutralize or eliminate pathogenic agents such as HIV, influenza, hepatitis B, or base on multiple epitopes to give more immunity. In cancer immunotherapy they are specific for tumor associated or individual antigens and thus kill cancer cells without affecting the normal cells (11). In autoimmune diseases, like autoimmunity to multiple sclerosis and type 1 diabetes, they can either trigger the regulation of immune tolerance or control epitope spreading. These vaccines which include the synthesized peptides of pathogens, mutated proteins also known as cancer vaccines or autoantigens elicit very high immune responses for numerous uses as shown in figure 2. These characteristics enhance the ability to apply them for personalized immunotherapy approaches therefore, increasing the probabilities of better outcomes (12). They bring a totally new strategy in vaccinology that, when applied to improving the efficiency and the duration of action of the vaccines, presents a great potential.



Fig. 2: Development of peptide-based vaccine

Advantages of Synthetic Peptides

Synthetic peptides therefore have several advantages in vaccinology and in other fields. They enable immune response targeting to specific pathogen, tumor or allergen related epitopes, thus reducing on-target effects which in turn increases the overall responsiveness of the treatment (13). This can help in the case of the specific medication where the reaction depends on the individual patient's hypersensitivity level, which is the core of cancer immunotherapy (14). Lack of live organism is one disadvantage but also a safety in whole-pathogen vaccines as compared to synthetic peptides as they do not harbor infections and are effective for immuno-compromised individuals (15). These are synthesized chemically, which makes them have high purity therefore, there are fewer chances of contamination and large-scale production at an affordable cost can be easily done. They are versatile because new development is fast in addressing new pathogens or variants in view of rapidly changing disease demands such as influenza or SARS-CoV2. When used in conjunction with adjuvants, peptides increase immunogenicity of vaccines, and can be incorporated into multi-peptide vaccines. They are specific, they do not react with other antigens but the target antigen, and the immune response produced is controlled, something important in handling autoimmune diseases. Besides, peptides are valuable in research work involved with the studying of immune mechanisms and as diagnostic agents in immune response analysis and disease prognosis.

Challenges and Limitations

Essential benefits of synthetic peptide vaccines are also important however, which accompanied the application of this method also has many critical problems that should be considered. First of all, they can have low immunogenicity because of the problems with replicating native conformations of proteins and the need to use appropriate adjuvants to enhance immunological reactions (16). Maintaining peptide stability throughout the manufacturing process and during shipping also remains a major challenge because of the inability of peptides to be protected from degradation yet be presented effectively to the immune cells. It means that epitopes can be variable among pathogens, and even among individuals; and this aspect can reduce the effectiveness of vaccines (17), if there are immune tolerance and cross-reactivity problems. However, for mature long-term effectiveness financial reports make it extremely difficult to optimize the use of synthetic peptide vaccines in different population. To overcome these challenges, research and development in many of these platforms will be important to improve on their effectiveness and safety in future immunization programs around the world (18).

Conclusion

Polypeptide vaccines are modern, specific and selective forms of vaccination tools in vaccinology that act on small antigen targets without affecting other sites. Issues include the small number of different epitopes that can be targeted in a vaccine and the generally difficult route of administration. Further developments in the design of peptides for vaccines, as well as in adjuvants, and the field of personalized vaccines indicate that the methods discussed above may be effective in other areas outside of infectious disease vaccine development. Addressing the existing constraints, improving the options extendibility, and making them more accessible are necessary for achieving maximum impacts in global health.

References

[1] Edition F. New Generation Vaccines.
[2] Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO molecular medicine. 2014;6(6):708-20.
[3] Steward M, Howard C. Synthetic peptides: a next generation of vaccines? Immunology Today. 1987;8(2):51-8.
[4] Taniuchi I. CD4 helper and CD8 cytotoxic T cell differentiation. Annual review of Immunology. 2018;36(1):579-601.
[5] Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Archivum immunologiae et therapiae experimentalis. 2008;56:77-83.
[6] Storni T, Kündig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Advanced drug delivery reviews. 2005;57(3):333-55.
[7] Rajčáni J, Szathmary S. Peptide vaccines: new trends for avoiding the autoimmune response. The Open Infectious Diseases Journal. 2018;10(1).
[8] Sprent J. T and B memory cells. Cell. 1994;76(2):315-22.
[9] Zerbe K, Moehle K, Robinson JA. Protein epitope mimetics: from new antibiotics to supramolecular synthetic vaccines. Accounts of chemical research. 2017;50(6):1323-31.
[10] García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. Apmis. 2014;122(4):257-67.
[11] Knutson KL, Disis M. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunology, Immunotherapy. 2005;54:721-8.
[12] Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer letters. 2014;352(1):113-25.
[13] Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: current trends in clinical application. Cell Proliferation. 2021;54(5):e13025.
[14] Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology. 2011;127(1):18-27.
[15] Sahu SR, Bose S, Singh M, Kumari P, Dutta A, Utkalaja BG, et al. Vaccines against candidiasis: Status, challenges and emerging opportunity. Frontiers in Cellular and Infection Microbiology. 2022;12:1002406.
[16] Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chemical science. 2016;7(2):842-54.
[17] Gershoni JM, Roitburd-Berman A, Siman-Tov DD, Freund NT, Weiss Y. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs. 2007;21:145-56.
[18] Duclos P, Okwo-Bele J-M, Gacic-Dobo M, Cherian T. Global immunization: status, progress, challenges and future. BMC international health and human rights. 2009;9:1-11